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1050-42 Roper fue ion  Therapy  With E i ther  Intravenous 
Thrombolya la  or  P r imary  PTCA In E lder ly  Pat ients  Is 
Beneficial: One-Year Results From a Nationwide French 
Registry of Acute Myocardial Infarction 
Nicolas Dsnchtn, Laurent Vaur, Nathalie Genes, Jean Ferrieres, Michael Angioi, Sylvia 
Etienne, Jean-Pierre Cambou, the USIK investigators, HEGP 20 rue Leblanc, Paris, 
France. 
Background: The role of early reperfusion therapy at the acute stage of MI in elderly 
patients is debated, Aim and Methods: The aim of this study was to analyze the prognos- 
tic role of reperfusion with IV thrombolysis or pdmary PTCA in the nationwide USIK data- 
base, which prospectively included all pts admitted to a CCU for an AMI in France in 
November 1995. For the purpose of the present study, only patients admitted within 24 
hours of AMI and with one-year follow-up available were included. Results: Of the 1,838 
patients included, 785 were • 70 years old, of whom 225 (29 %) had early reperfusion 
therapy with thrombolysis (n=173) or primary PTCA (n=52). Patients treated with early 
reperfusion had a baseline profile that differed from that of patients treated convention- 
ally: women (31% vs 50 %, p < 0,001), admission within 6 hours of symptom onset (84 
% vs 54 %, p < 0.001), history of systemic hypertension (48 % vs 60 % p < 0,002), history 
of stroke (5 % vs 11%, p < 0.01), peripheral artedal disease (8 % vs 18 %, p < 0.001); 
congestive heart failure (5 % vs 20 %, p < 0.001), previous MI (12 % vs 25 %, p < 0,001 ), 
anterior location of current MI (40 % vs 28 %, p < 0,002). Overall one-year Kaplan-Meier 
survival was 78 % for patients with versus 64 % for those without reperfusion therapy (p 
< 0.01). Cox multivariate analysis showed that reperfusion therapy was an independent 
predictor of survival (RR 0.71; 95% CI: 0.50-0,99), along with age (RR: 1.04, 95% Ch 
1.02-1,07), anterior location of MI (RR: 2.14, 95 % Cl: 1.64-2,80), history of stroke (RR: 
1.81, 95 % CI: 1,25-2.61), and history of congestive heart failure (RR: 1,66, 95 % CI: 
1.18-2.32). When the analysis was repeated after exclusion of the patients who under- 
went primary PTCA, treatment with IV thrombolysis was also associated with higher one- 
year survival, and thrombolysis was of borderline statistical significance in the Cox multi- 
variate analysis (RR: 0.72, 95 % CI: 0.50-1.04, p=0.08). Conclusions: data from this large 
"real life" registry indicate that reperfusion therapy with either thrombolysis or primary 
PTCA is associated with improved one-yeer survival in patients over 70 years of age. 
1050-43 Gender Is an Independent Predictor of Both In-Hospital 
and One-Year Outcomes Following Pr imary  In tervent ion  
for Acute Myocardial In farct ion 
Kimbarlv A. Skeldino. Kishore Harjai, Laxmi Mehta, Gregg W. Stone, David A, Cox, 
Judith A, Boura, Lorelei L Grines, William W. O'Neill, Cindy L Grines, William Beaumont 
Hospital, Royal Oak, Michigan. 
Background: Prior studies have indicated that female gender contributes to worse prog- 
nosis from acute myocardial infarction (MI), elective percutaneous intervention (PCI), 
and coronary artery bypass grafting (CABG). However the impact of gender on outcomes 
following primary angioplasty for acute MI is not well established. 
Methods: We evaluated the outcomes of 3401 patients from the PAMI studies receiving 
primary intervention for acute MI, of whom 27% were female. Clinical data, angiographic 
details and outcomes were evaluated. 
Results: Females were older (66¢12 vs 59+12, p=0.00Ol ), more often diabetic (22% vs 
14%, p--O.001), and hypertensive (57% vs 42%, p=0.001). They more often had prior 
congestive heart failure (3,4% vs 1.9%, p=O.009), and cerebrovascular events (9% vs 
4%, p=0.001). Females were less often current smokers (36% vs 44%, p=0.001), had 
less incidence of prior CABG (2.6% vs 4.7%, p=0.010), prior Mi (12% vs 15%, p=0,020), 
and prior PCI (7.7% vs 10.3%, p=0,021), Angiographically, patients were similar: initial % 
stanosis (98+6 vs 98+5, p=0.180), ejection fraction (48+12 vs 49+12, p=0,594), final % 
stenosis (15+17 vs 15¢17, p=0.881) and TIMI flow pre (p=0.108) and post (p=0.747) pro- 
cedure. Females had less muitivessel disease (44% vs 49%, p=0,006). Females had 
higher in hospital death (4.6% vs 2.3%, p=0.001), death at 1 year (10% vs 6%, p=0.001) 
and target vessel revascularization (TVR) at 1 year (18% vs 13%, p=O.005). Adjusted for 
baseline differences, females remained at higher risk of in-hospital cardiovascular events 
including TVR, disabling stroke, reinfarction or death following primary PCI (8.7% vs 
5.7%, p--0.001). This difference continues at 1 year (27% vs 19%, p=0,001). On multi- 
variate analysis female gender is an independent predictor for in-hospital events 
(p=0.0025, OR=1.634, 95% C1=1.189-2.247) and remains predictive at 1 year 
(p=<0.0001, OR=1.553, 95%CI 1.258-1.916), 
Conclusions: This data suggests that female gender is a significant independent predic- 
tor of major cardiovascular events at one year following primary PCI for acute MI. Further 
study is needed to determine if additional clinical and/or angiographic conditions also 
contribute to this difference. 
1050-44 Outcomes for Asian Indians Following Acute ST 
E levat ion Myocardial Infarction: Results From the  
GUSTO Trials 
Vanu Menon. Lilin She, Rabia Arshad, Anne S. Hellkamp, Sunil V. Rao, Judith S. 
Hochman, E Magnus Ohman, St Lukes Rooseveit, NY, New York. 
Background: Relative outcomes following thrombolytic therapy for Asian Indians (AI) 
compared to Caucasians (C) have not been reported. Methods: We compared clinical 
Outcomes in 475 AI enrolled in GUSTO-I (1990-3) GUSTO lib (1993-5) and GUSTO-Ill 
(1995-7) and compared them to 54799 C. Results: AI were significantly younger, shorter 
and Jightar than C (all P< 0.001 ). They were more likely to be male, have a history of dia- 
betes but were less likely to be current smokers ( all P < 0.001). Time to treatment, pre- 
senting heart rate, rates of hypertension and hypercholestarolemia were similar (all p = 
NS). Despite lower rates of angiography (37% vs 53%, p = 0.0001) and diminished left 
ventricular function in AI (47.7 ± 14.2 vs 51.5 ± 13.2, p = 0.004), distribution of 1-2-3 ves- 
sel disease were similar. Although rates of moderate/severe bleeding were comparable, 
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AI had less strokes (0.21 vs 1.47%, p = 0.04). Overall 30 day and 1 year mortality for AI 
(6.99 vs 8.00% and 11.04% vs 11.36%) were similar as were rates of reinfarction and 
shock. Thirty day (OR 1.399, 95% C[ 0.878, 2.230, p= 0.16) and 1 year mortality (OR 
1.144, 95% CI 0.770, 1.699, p = 0.51) for AI remained similar to C after adjusting for age, 
gender, weight, height, systolic BP, Killip Class, heart rate, diabetes, hypertension, infarct 
location, smoking status, time to treatment, rates of previous MI, prior CABG, prior stroke 
and angina, as well as US location of enrollment. Amongst countries enrolling a large 
number of AI, observed 30 day mortality rates for AI in Canada (n = 200), USA (n = 108) 
and South Africa (n = 79) were 7.5%, 5.6% and 13.9% respectively. Conclusion: 30 day 
and 1 year mortality for AI are similar to C following acute ST elevation MI. Regional dif- 
ferences in outcome deserve further exploration. 
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1051-27 Predict ing and Preventing Myocardial In farct ion  With 
C lop idogre l  in Pat ients  With Symptomatic 
Atherothromboais: Results From CAPRIE 
Christopher P. Cannon. on behalf of the CAPRIE Investigators, Brigham and Women's 
Hospital, Boston, Massachusetts. 
Background: Prevention of myocardial infarction (MI) is a major goal of therapy in 
patients (Pts) with documented atherothrombosis. Identification of Pts at higher dsk of 
developing a subsequent MI may assist in selecting more aggressive therapy for these 
Pts to prevent of MI. Although prediction rules now exist for mortality, few prediction rules 
exist for ML Also, factors that predict mortality (usually related to left ventricular failure) 
may not be the same as predictors of ML Methods: In the CAPRIE trial 19,185 Pts with 
recent prior MI, stroke or documented peripheral arterial disease were randomized to 
receive clopidogrel or aspidn (ASA), We used multivariate (MV) analysis to develop a risk 
score for MI. Results: A new MI occurred in 5,04% of Pts treated with ASA vs. 4,20% for 
clopidogrel, a 19.2% relative reduction, p=0,008. MV predictors of MI were: Prior MI 
(p<0.0001), prior angina (p<O.0001), prior peripheral arterial disease (p<0.0001), highest 
quartile of creatinine (p<0,0001), diabetes (p=0.013), age _> 65 years (p=0.015), prior 
stroke (p=0.0497) and treatment with clopidogrel (O.R. = 0.80, adjusted p=0.0067). 
When stratifying by number of risk factors, the benefit of clopidogrel was an absoJute 
1,3% reduction in MI in Pts with 1-2 risk factors, and 5.2% in Pts with 5 or more risk fac- 
tors.(Figure) Conclusions: Risk of MI can be predicted across a 4 fold range, from 4 to 
17% over 3 years. Benefit of clopidogrel was seen in both low and high risk subgroups, 
supporting its use in a wide spectrum of patients. 
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1051-28 Ramipril Prevents Major Cardiovascular Events in High- 
Risk Women: Results of  the  HOPE Trial 
Eva Lonn, Rosa Roccaforte, Qilong Yi, Jacqueline Bosch, Jeffrey Probsffield, Peter 
Steight, GiUes Dagenais, Salim Yusuf, McMaster Universi~ Hamilton, Ontario, Canada. 
Background: it has been suggested based on subgroup analyses in heart failure (HF) 
and/or post myocardial infarction (MI) trials, that ACE inhibitors may be less effective in 
women than in men. These studies have generally included few women and were thus 
not adequately powered to assess the effects of ACE inhibitors in women. Furthermore, 
there are no data in women without HF and with preserved left ventdcular ejection frac- 
tion (LVEF). 
Methods: In the Heart Outcome Prevention Evaluation (HOPE) trial we enrolled a large 
number of women, who were at least 55 years of age and had documented vascular dis- 
ease or diabetes and additional risk factor(s)without HF and with preserved LVEF. 
Patients were randomized to ramipri110rag/day or placebo and mean follow up was 4.5 
years. Treatment effects in women were eva)uatad as a preplanned subgroup analysis. 
Results: There were 2,480 women. At baseline the placebo and ramipril groups were well 
balanced. Mean age was 66.5 years, 1,642 (66%) women had a history of CAD, 929 
(37%) had prior MI, 273 (11%) had pdor stroke or TIA, 1322 (53%) had diabetes and 
1496 (60%) hypertension. Treatment with ramipril resulted in a significant reduction in the 
primary outcome, the composite of MI, stroke and CV death and in other Outcomes of 
interest (Table). There was no difference (lack of statistical heterogeneity) in the magni- 
